Hiroshi Tanaka

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT

Kazuhiro Sanpei, Hiroki Takano, S. Igarashi et al. · Nature Genetics · 1996 · 774 citations

Life Sciences, Genetics, Molecular Genetics +17

Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth

Tsutomu Ohta, Kumiko Iijima, Mamiko Miyamoto et al. · Cancer Research · 2008 · 628 citations

Medicine, Genetics, Oncology +15

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells

Carsten O. Daub, Kristoffer Vitting‐Seerup, Robin Andersson et al. · Science · 2015 · 609 citations · Full text

Life Sciences, Genetics, Molecular Biology +17